QC
RLAY icon

Quantessence Capital’s Relay Therapeutics RLAY Stock Holding History

Quantessence Capital’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,650
Closed -$33.1K – 393
2025
Q1 		$33.1K Buy
+12,650
New +$49.6K 0.01% 330

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Quantessence Capital's RLAY Position: Q2 2025 in Review

Quantessence Capital sold out of Relay Therapeutics (RLAY) in Q2 2025, closing a stake of 12,650 shares — an estimated $33.1K sold.

Quantessence Capital first reported a position in RLAY in Q1 2025 and held it in 1 quarter. The position peaked at $33.1K in Q1 2025. 208 funds tracked by Wall St. Rank hold RLAY as of Q2 2025.

  • Quantessence Capital reported no remaining Relay Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Quantessence Capital sold 12,650 Relay Therapeutics shares in Q2 2025, an estimated $33.1K.
  • Quantessence Capital first reported a position in Relay Therapeutics in Q1 2025 and held it in 1 quarter.
  • Quantessence Capital's Relay Therapeutics position peaked at $33.1K in Q1 2025.
  • 208 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2025.

Based on Quantessence Capital's 13F filing for Q2 2025, filed 14 Aug 2025.